X4 Pharmaceuticals, Inc — Director's Dealing 2019

Apr 3, 2019

SEC Form 4/A — Form 4/A

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2019-03-13

Reporting Person: BLECH ISAAC (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-13	Stock Option (right to buy)	$6.84	A	70796	Acquired	2025-12-14	Common Stock (70796)	Direct
2019-03-13	Stock Option (right to buy)	$18.66	A	6854	Acquired	2029-03-13	Common Stock (6854)	Direct

Footnotes

F1: Fully vested.

F2: Reflects the Reporting Person's stock option to acquire 744,967 shares of X4 common stock for $0.65 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger").

F3: 33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger.